They can accomplish this by transcriptionally activating the expression of the immune checkpoints PD-L1 and PD-L2, as well as post-translationally enhancing their stability (e.g., via glycodecoration) on the cancer cell membrane (52–57). This evidence concerns the gene PDCD1LG2 and cancer.